KUKJEON PHARMACEUTICAL Inkomsten in het verleden
Verleden criteriumcontroles 0/6
KUKJEON PHARMACEUTICAL's earnings have been declining at an average annual rate of -43%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 17% per year. KUKJEON PHARMACEUTICAL's return on equity is 4.7%, and it has net margins of 4%.
Belangrijke informatie
-43.0%
Groei van de winst
-43.0%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 11.3% |
| Inkomstengroei | 17.0% |
| Rendement op eigen vermogen | 4.7% |
| Nettomarge | 4.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe KUKJEON PHARMACEUTICAL geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 133,272 | 5,355 | 14,641 | 4,939 |
| 31 Mar 24 | 129,429 | 1,351 | 13,584 | 4,630 |
| 31 Dec 23 | 121,998 | 4,824 | 12,807 | 4,821 |
| 30 Sep 23 | 116,685 | 9,496 | 12,864 | 4,699 |
| 30 Jun 23 | 113,905 | 9,389 | 12,346 | 4,472 |
| 31 Mar 23 | 110,274 | 12,212 | 12,049 | 4,370 |
| 31 Dec 22 | 103,711 | 8,948 | 11,469 | 3,981 |
| 30 Sep 22 | 102,731 | 1,603 | 10,807 | 3,955 |
| 30 Jun 22 | 97,094 | 3,674 | 9,702 | 3,764 |
| 31 Dec 21 | 85,354 | 4,038 | 8,838 | 2,651 |
Kwaliteitswinsten: A307750 has a large one-off gain of ₩410.0M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: A307750's current net profit margins (4%) are lower than last year (8.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if A307750's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: A307750's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: A307750 had negative earnings growth (-43%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.9%).
Rendement op eigen vermogen
Hoge ROE: A307750's Return on Equity (4.7%) is considered low.